Talk:Sarilumab

Pharmacology Mid‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Medicine Mid‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Sarilumab.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

Add mechanism

Could add a brief Mechanism of action section to explain why thought useful for RA and ankylosing spondylitis and any other potential indications ? - Rod57 (talk) 12:21, 24 November 2016 (UTC)[reply]

Could (? should) be added to Anti-IL-6, as this is a class effect, and not limited to one single moiety. WhitePJ 20170421 12:50 —Preceding undated comment added 11:50, 21 April 2017 (UTC)[reply]

Other phase 3 trials

The TARGET and MOBILITY trials were also positive - FDA Gives Nod to Sarilumab for Rheumatoid Arthritis 2017 - Rod57 (talk) 17:53, 12 June 2017 (UTC)[reply]

EMA (EU) approval

[1] says "The EMA has cleared Kevzara for use in combination with methotrexate for the treatment of moderately to severely active rheumatoid arthritis in adults who have responded inadequately to - or who are intolerant to - one or more disease modifying anti-rheumatic drugs (DMARDs)." - but need a better source. - Rod57 (talk) 12:21, 5 July 2017 (UTC)[reply]